NCT02437136
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02437136
Title Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Syndax Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field